There are a number of catalysts on the horizon for global pharma stocks, but Jefferies has dialed back expectations for a number of stocks in the space. In a new report, analyst Jeffrey Holford has updated the firm’s outlook and price targets for the biggest names in the pharma space.
Despite lowering a number of price targets, Jefferies is excited about the potential for top pick AbbVie Inc ABBV 0.78%.
“We expect that the PTAB decision whether or not to institute IPR on the CHRS challenge to ABBV’s ‘135 RA closing patent will be one of the most significant catalysts in the near future,” Holford explained.
Jefferies predicts roughly a $9/share gain for AbbVie’s stock in the case of denial and a $3/share decline in the case of institution.
Jefferies maintains a Buy rating and $90 price target for AbbVie.
It’s Not All About AbbVie
In addition, the firm has reduced price targets for the following U.S.-listed stocks:
- Abbott Laboratories ABT 1.05%: to $44
- Eli Lilly and Co LLY 0.49%: to $100
- Johnson & Johnson JNJ 0.59%: to $108)
Jefferies also upped…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
